Zevra Therapeutics SG&A Expense (Quarterly) Analysis

Zevra Therapeutics Inc (ZVRA)

4.73 -0.03 (-0.63%) USD | NASDAQ | May 17, 16:00

4.73 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
March 31, 2024	9.931M
December 31, 2023	14.66M
September 30, 2023	5.818M
June 30, 2023	7.005M
March 31, 2023	7.227M
December 31, 2022	4.772M
September 30, 2022	3.974M
June 30, 2022	3.558M
March 31, 2022	2.734M
December 31, 2021	2.556M
September 30, 2021	1.948M
June 30, 2021	2.305M
March 31, 2021	1.892M
December 31, 2020	2.528M
September 30, 2020	1.429M
June 30, 2020	1.719M
March 31, 2020	2.245M
December 31, 2019	1.376M
September 30, 2019	3.613M
June 30, 2019	2.989M
March 31, 2019	2.838M

Date	Value
December 31, 2018	2.964M
September 30, 2018	2.992M
June 30, 2018	3.42M
March 31, 2018	3.132M
December 31, 2017	2.614M
September 30, 2017	3.319M
June 30, 2017	3.574M
March 31, 2017	3.266M
December 31, 2016	2.873M
September 30, 2016	3.104M
June 30, 2016	4.287M
March 31, 2016	3.736M
December 31, 2015	2.566M
September 30, 2015	2.152M
June 30, 2015	3.188M
March 31, 2015	0.977M
December 31, 2014	1.577M
September 30, 2014	1.086M
June 30, 2014	1.33M
March 31, 2014	0.534M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.376M

Minimum

Dec 2019

14.66M

Maximum

Dec 2023

4.214M

Average

2.862M

Median

SG&A Expense (Quarterly) Benchmarks